SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report: February 7, 1996
INTERNEURON PHARMACEUTICALS, INC.
- - --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
DELAWARE
- - --------------------------------------------------------------------------------
(State of other jurisdiction of incorporation)
0-18728 043047911
- - ----------------------- ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
ONE LEDGEMONT CENTER, 99 HAYDEN AVENUE, LEXINGTON, MASSACHUSETTS 02173
- - --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone no. including area code: (617) 861-8444
---------------
-1-
<PAGE>
Item 5. OTHER EVENTS
On February 7, 1996, a majority-owned subsidiary of the Registrant,
Intercardia, Inc. ("Intercardia"), completed its initial public offering of
2,530,000 shares of Common Stock, including 330,000 shares which were subject to
the underwriters' over-allotment option, at $15.00 per share. The offering
resulted in net proceeds to Intercardia of approximately $35,003,500, after
deducting underwriting discounts and estimated expenses of the offering. Of
these shares, 333,333 were purchased by the Registrant at the offering for an
aggregate purchase price of approximately $5 million.
As a result of this offering, the Registrant owns approximately 60% of
Intercardia's Common Stock.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERNEURON PHARMACEUTICALS INC.
By: /S/ GLENN L. COOPER, M.D.
-------------------------------------
Glenn L. Cooper, M.D.
President and Chief Executive Officer
Dated: February 7, 1996
-3-
